Explore the vast range of titles available.

Psychosocial support became a crucial part of healthcare in the new reality. [...]several volunteer groups help to transfer patients to neighboring countries if there is such a need. To date, many Ukrainian centers have resumed their work, but if it is not possible to provide care for patients, the Polish healthcare system still has the capacity to help oncological patients from Ukraine, and the Polish Society of Gynecologic Oncology provides the support for them. To let us know about a patient in need, you can fill in the online form providing us some details and contact information: https://docs.google.com/forms/d/1d9456VgayN_mrBxXUS8f_pUl_eXwPmhfIcGoA4Bmc30/viewform?edit_requested=true For further details check the website: https://ptgo.pl/help-for-ukrainian-patients/ You may also contact us via email: ukraina@ptgo.pl Ethics statements Patient consent for publication Not applicable.

Introduction/BackgroundIn 2022, over 8.2 million refugees were recorded across Europe after the Russian invasion in Ukraine. As every human crisis, the war is associated with changes in access to medical care. Due to the cervical cancer pathogenesis, results of compromised prevention may become visible after years since the beginning of war. The aim of the study was to evaluate experience of European centres in cervical cancer prevention among Ukrainian refugees.MethodologyThis was a cross-sectional questionnaire based study. Questionnaires were distributed among clinicians from the European Network of Young Gynae Oncologists (ENYGO) network until August 2022. Our survey included questions about managing patients who voluntary reported exclusively for the purpose of cervical cancer screening or treatment of preinvasive cervical lesions.ResultsOur analysis included data obtained from 38 respondents practicing in Germany, Hungary, Italy, Norway, Poland, Romania, Slovenia, Spain, Turkey, and the UK. More than one third of these centres were accredited by the European Society of Gynaecological Oncology (ESGO).Seven (17%) centres reported participation in Ukrainian refugees gynaecological cancer prevention measures. Seven (17%) respondent sites collected Pap smear or human papillomavirus (HPV) test. Three (7%) centres reported demand for HPV vaccination from the Ukrainian refugees.Seven (17%) clinical centres managed Ukrainian refugees with precancerous cervical lesions. More than half of these patients (54%) required primary invasive treatment. 15% were admitted for continuation of treatment. 7% required follow-up after treatment. 23% underwent further diagnostic regimen without indication for invasive treatment.ConclusionPrevention and treatment of cervical lesions in terms of war in Ukraine pose significant challenge both for European healthcare providers and Ukrainian refugees. The results obtained in present study show that even in specialized oncologic centres, which are mostly dedicated to treat invasive disease, Ukrainian refugees report and require both preventive and curative services of cervical lesions.DisclosuresNothing to disclose

This is a report from the European Society of Gynaecological Oncology State-of-the-Art Virtual Meeting held December 14–16, 2020. The unique 3-day conference offered comprehensive state-of-the-art summaries on the major advances in the treatment of different types of gynecological cancers. Sessions opened with a case presentation followed by a keynote lecture and interactive debates with opinion leaders in the field. The speakers also presented scientific reviews on the clinical trial landscape in collaboration with the European Network of Gynecological Oncological Trial (ENGOT) groups. In addition, the new ESGO-ESRTO-ESP endometrial cancer guidelines were officially presented in public. This paper describes the key information and latest studies that were presented for the first time at the conference.

This is a report from the 22nd Meeting of the European Society of Gynaecological Oncology, held October 23–25, 2021. The 3-day event offered an educational experience covering the major scientific and clinical advances in gynecological oncology. The Congress program included different session formats, including guidelines updates and state-of-the-art lectures. This article provides an overview of the main Congress activities as well as of the most important studies that were presented at the event for the first time.

Best of ESGO 2022 includes a selection of best original research presented during the 23rd European Congress on Gynaecological Oncology between October 27 and 30, 2022 in Berlin. Out of 1107 submitted abstracts, authors of studies which obtained the highest scores in a blinded review process were invited to present their results during four oral sessions, young investigators session, and oral poster sessions. By means of this publication, we aim to provide readers with an overview of the best quality research presented at the European Society of Gynaecological Oncology (ESGO) 2022.

BackgroundThe European Society of Gynaecological Oncology (ESGO) and partners are committed to improving the training for gynecologic oncology fellows. The aim of this survey was to assess the type and level of training in cervical cancer surgery and to investigate whether the Laparoscopic Approach to Cervical Cancer (LACC) trial results impacted training in radical surgery for gynecologic oncology fellows.MethodsIn June 2020, a 47-question electronic survey was shared with European Network of Young Gynaecologic Oncologists (ENYGO) members. Specialist fellows in obstetrics and gynecology, and gynecologic oncology, from high- and low-volume centers, who started training between January 1, 2017 and January 1, 2020 or started before January 1, 2017 but finished their training at least 6 months after the LACC trial publication (October 2018), were included.Results81 of 125 (64.8%) respondents were included. The median time from the start of the fellowship to completion of the survey was 28 months (range 6–48). 56 (69.1%) respondents were still fellows-in-training. 6 of 56 (10.7%) and 14 of 25 (56.0%) respondents who were still in training and completed the fellowship, respectively, performed ≥10 radical hysterectomies during their training. Fellows trained in an ESGO accredited center had a higher chance to perform sentinel lymph node biopsy (60.4% vs 30.3%; p=0.027). There was no difference in the mean number of radical hysterectomies performed by fellows during fellowship before and after the LACC trial publication (8±12.0 vs 7±8.4, respectively; p=0.46). A significant reduction in number of minimally invasive radical hysterectomies was noted when comparing the period before and after the LACC trial (38.5% vs 13.8%, respectively; p<0.001).ConclusionExposure to radical surgery for cervical cancer among gynecologic oncology fellows is low. Centralization of cervical cancer cases to high-volume centers may provide an increase in fellows’ exposure to radical procedures. The LACC trial publication was associated with a decrease in minimally invasive radical hysterectomies performed by fellows.

Background The impact of the COVID‐19 pandemic on European gynaecological cancer patients under active treatment or follow‐up has not been documented. We sought to capture the patient perceptions of the COVID‐19 implications and the worldwide imposed treatment modifications. Methods A patient survey was conducted in 16 European countries, using a new COVID‐19‐related questionnaire, developed by ENGAGe and the Hospital Anxiety & Depression Scale questionnaire (HADS). The survey was promoted by national patient advocacy groups and charitable organisations. Findings We collected 1388 forms; 592 online and 796 hard‐copy (May, 2020). We excluded 137 due to missing data. Median patients’ age was 55 years (range: 18–89), 54.7% had ovarian cancer and 15.5% were preoperative. Even though 73.2% of patients named cancer as a risk factor for COVID‐19, only 17.5% were more afraid of COVID‐19 than their cancer condition, with advanced age (>70 years) as the only significant risk factor for that. Overall, 71% were concerned about cancer progression if their treatment/follow‐up was cancelled/postponed. Most patients (64%) had their care continued as planned, but 72.3% (n = 892) said that they received no information around overall COVID‐19 infection rates of patients and staff, testing or measures taken in their treating hospital. Mean HADS Anxiety and Depression Scores were 8.8 (range: 5.3–12) and 8.1 (range: 3.8–13.4), respectively. Multivariate analysis identified high HADS‐depression scores, having experienced modifications of care due to the pandemic and concern about not being able to visit their doctor as independent predictors of patients’ anxiety. Interpretation Gynaecological cancer patients expressed significant anxiety about progression of their disease due to modifications of care related to the COVID‐19 pandemic and wished to pursue their treatment as planned despite the associated risks. Healthcare professionals should take this into consideration when making decisions that impact patients care in times of crisis and to develop initiatives to improve patients’ communication and education. Gynaecological cancer patients in Europe appeal for more transparency and continuation of high standard oncologic care even in times of crisis like the COVID‐19 pandemic.

Introduction/BackgroundGender-related differences in career development are well-known issues in various professions. An international survey on gender-related differences was performed among young gynecologic oncologic surgeons in Europe to identify potential gender inequalities in career development.MethodologyA survey on demographics, clinical and academic working environment, family/parenting, career development, salary and leadership was sent to all members of the European Network of Young Gynecologic Oncologists. Gynecologic oncology surgeons and obstetricians/gynecologists who actively work in this field in Europe were included in the study.ResultsResponses were analyzed from 192 gynecologic oncology surgeons of whom 125 (65.1%) were female (median age 37, IQR: 34–42) and 67 (34.9%) male (median age 38, IQR: 36–41). Men reported to perform median 15 and women median 10 operations monthly (p = .007). Among women, 24.8% had a leadership position vs. 44.8% among men (crude OR = 2.46, 95% CI 1.31–4.62, p < .01). When stratifying for age under 41 and having children, 36.7% men and 5.6% women had a leadership position (adjusted OR 10.8, 95% CI 3.28–35.64, p < .001). Significantly higher proportion of women than men believed they earned less than their gender counterparts at the same clinical position and with same qualifications (30.4% vs. 2.5%, p < .001). There wasn’t a statistically significant difference between academic qualification (PhD degree and/or professorship) and gender (p = .92 and p = .64), accordingly. In the previous year, men published more peer-reviewed articles than women (median=3 vs. median=2; p = .017).ConclusionOur comprehensive analysis revealed gender disparity in several aspects among the young generation of gynecologic oncology surgeons, especially pronounced in leadership positions. New initiatives from ENYGO/ESGO are warranted to better understand the attrition of women on the way from training to leadership positions in gynecological oncology, to overcome the identified obstacles and to help elimination of the gender gaps.

Introduction/BackgroundThe representation of female leadership acrossdifferent medical specialities does not reach parity. It is even more evidentin surgical specialities like gynaecological oncology. The primary aim of thisstudy was to analyse gender distribution of invited speakers during ESGOCongresses.MethodologyIn this cross-sectional study, we analysed data fromESGO Congresses in 2017, 2019, and 2021.We identified gender of chairpersons &presenters (together they represent the invited congress faculty) according tothe given full name in the congress program. We used Google search when wecould not identify gender according to the given name. We analysed the databased on gender of chairpersons, presenters, and female-to-male ratios insessions. We excluded ‘glass with an expert’ talks and ceremonial sessions,such as opening and closing ceremonies. As a subgroup, we investigated genderdistribution in sessions of the European Network of Young GynaecologicOncologists (ENYGO).ResultsIn the pooled analysis of all 3 congresses, weidentified a total of 516 chairpersons/speakers with a female to male ratio of0.66. In 2017 female faculty contribution was 30%, in 2019 41% and in 2021 31%.In the pooled analysis, scientific programmecommittees consisted of 65% male and 35% members. The female contribution toscientific programme committee was stable among the 3 analysed congresses. In 2017 and 2021 the scientific programmecommittee was chaired by a man, respectively, in 2019 by a female. In all 3 congresses there was a substantially highernumber of pure male sessions (chairs & presenters are male only) than pure femalesessions. The number of pure male sessions decreased over time in the 3analysed congresses.ConclusionESGO has implemented the general rule of genderbalance into ESGO congress Standard Operating Procedures (SOPs) in 2020, inaddition to country balance and interdisciplinary approach. Based on ouranalysis, ESGO congresses have an acknowledgeable-level of gender balance. Amore comprehensive analysis with more details will be provide at the ESGOcongress in Berlin.

ObjectiveBoth the location of primary disease and treatment side effects may have an impact on sexual function in oncogynecological patients. The aim of this study was to examine the prevalence, strategies, difficulties, and ideas for improvement in sexual counseling among specialists managing patients with gynecologic malignancies.MethodsThis was a cross-sectional survey study performed among healthcare professionals treating patients with gynecologic malignancies. A self-prepared questionnaire included 61 questions concerning general demographic information and different aspects of sexual counseling in the gynecologic oncology practice. Analysis included attitudes, behaviors, management strategies, difficulties, and ideas for possible systemic improvements. Statistical analysis involved descriptive statistics, two-sided chi-square test, and Fisher’s exact test.ResultsA total of 150 respondents from 46 countries answered the survey. The majority of survey participants stated that sexual counseling of oncological patients is very important (n=73, 49%) or important (n=46, 31%). One hundred and two (68%) respondents agreed that sexual counseling of gynecologic oncology patients should be routinely provided by the specialist managing the primary disease. However, collecting information concerning sexual function is performed often or always by only 21% of respondents and 19% discuss the topic rarely or never. The most frequently indicated barriers leading to difficulties in sexual counseling include lack of time (74%), lack of specialist knowledge (55%), and patient embarrassment (48%). One hundred and seven (71%) respondents expressed interest in participating in sexual counseling workshops organized by the European Society of Gynaecological Oncology (ESGO)/European Network of Young Gynaecological Oncologists (ENYGO), 74 (49%) would like to access webinars on the topic, and 120 (80%) would be interested in materials in the ESGO online educational resources.ConclusionOne of the proposed solutions to insufficient access to sexual care for women with gynecologic malignancies is providing access to specialist educational programs for both patients and healthcare specialists.